Selfotel is a NMDA receptor antagonist.

NMDA:50 nM

CGS 19755 reduces neuronal death concentration-dependently as assessed by phase-contrast microscopy and by measurement of LDH release into the bathing medium 20-24 h later with the mean (±SD) ED50 for CGS 19755 against NMDA toxicity of 25.4 ± 30.8 μM, determined from 6 experiments, each using 4 cultures per condition[1].

Selfotel blocks the harmaline-induced increase in cerebellar cyclic GMP levels (4 mg/kg i.p. 2 hr) and inhibits convulsions elicited by maximal electroshock in rats with ED50 of 3.8 mg/kg at 1 hr after i.p. administration and in mice with ED50 of 2.0 mg/kg at 0.5 hr after i.p. administration)[1]. P.O. administration of Selfotel by gavage has little or no effect in an experimental model of anxiety in rats while Selfotel significantly increases conflict responding within a relatively narrow dose range at the minimum effective dose of 1.73 mg/kg i.p.[2].